Effects of Thai Dance Meditation Exercise on Renal and Cerebrovascular Function in Elderly With Diabetic Kidney Disease
NCT Number: NCT06578325
Status: COMPLETED
Study Type: INTERVENTIONAL
Phases: NA
Conditions: Diabetic Kidney Disease
Interventions: OTHER: Thai dance meditation|OTHER: No intervention
Sponsor: Chulalongkorn University
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 40
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2021-08-15
Completion Date: 2022-07-31
Locations: Faculty of Sports Science, Chulalongkorn University, Pathum Wan, Bangkok, 10330, Thailand

Summary:
Elderly with diabetic kidney disease who practiced Thai dance meditation training more favorable adaptations than normal daily life in improving glycemic control, kidney function, vascular function and cerebrovascular function.

Primary Outcome Measures: Blood pressure, Blood pressure (systolic blood pressure, diastolic blood pressure, and mean arterial pressure) in mmHg will be measured with automated blood pressure in mmHg device (CARESCAPE V100, GE Dinamap)., Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks.]|Heart rate, Heart rate in beats per minute will be measured with automated blood pressure in beat per minute device (CARESCAPE V100, GE Dina map)., Change from baseline heart rate at 12 weeks|Body fat, Body fat in percent will be measured with dual energy x-ray absorptiometry in percent (Prodigy-Pro, GE healthcare)., Change from baseline body fat at 12 weeks|Muscle mass and Weight, Muscle mass and weight in kilograms will be measured with dual energy x-ray absorptiometry in kilogram (Prodigy-Pro, GE healthcare)., Change from baseline muscle mass and weight at 12 weeks.|Arterial stiffness, Arterial stiffness will be measured with brachial-ankle pulse wave velocity in centimeter per second (VP-1000 plus, omrom Healthcare)., Change from baseline brachial-ankle pulse wave velocity at 12 weeks|Macro vascular function, Macro vascular function will be measured by brachial artery flow-mediated dilatation in percent with ultrasonography equipment EPIQ 5G, Phillips., Change from baseline brachial artery flow-mediated dilatation at 12 weeks|Renal function, Blood urea nitrogen (BUN) in milligram per deciliter will be measure by Kinetic test with urease and glutamate dehydrogenase with urease/glutamate dehydrogenase coupled enzymatic (Coupled enzymes), Change from baseline Blood urea nitrogen at 12 weeks.|Intrarenal artery, Intrarenal artery will be measured by renal blood flow in renal arterial resistive index (RI) with ultrasonography equipment EPIQ 5G, Phillips., Change from baseline renal arterial resistive index (RI) at 12 weeks.|Post Occlusive Reactive Hyperemia; PORH, Evaluation of blood flow to the skin area in percent will be measured by Post Occlusive Reactive Hyperemia in percent; PORH with Laser Doppler flowmeter, Perimed AB, Sweden., Change from baseline Post Occlusive Reactive Hyperemia; PORH at 12 weeks.|Cerebral blood flow, Cerebral blood flow in centimeter per second will be measure with ultrasonography equipment (EPIQ 5G, Phillips)., Change from baseline cerebral blood flow at 12 weeks|Cerebrovascular conductance index, Cerebrovascular conductance index in cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips)., Change from baseline cerebrovascular conductance index at 12 weeks|Cerebrovascular reactivity index, Cerebrovascular reactivity index in %cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips)., Change from baseline cerebrovascular reactivity index at 12 weeks|Arterial compliance, Arterial compliance in units will be measure by carotid diameter during systolic and diastolic with ultrasonography equipment (EPIQ 5G, Phillips) and systemic blood pressure with (VP-1000 plus, omrom Healthcare)., Change from baseline Arterial compliance at 12 weeks|Pulsatility index, Pulsatility index in units will be measure with ultrasonography equipment (EPIQ 5G, Phillips)., Change from baseline Pulsatility index at 12 weeks.] 12.Montreal Cognitive Assessment|Montreal Cognitive Assessment, Montreal Cognitive Assessment in score (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function., Change from baseline Montreal Cognitive Assessment at 12 weeks.]|Mini-Mental State Examination, Mini-Mental State Examination in scores (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function., Change from baseline Mini-Mental State Examination at 12 weeks.]|Trail Making Test-B, Trail Making Test-B in second cut off below 101 seconds that indicate dementia., Change from baseline Trail Making Test-B at 12 weeks|Fasting blood sugar, Fasting blood sugar in mg/dl will be measure with enzymatic assay using hexokinase reaction., Change from baseline fasting blood sugar at 12 weeks.]|Glycosylated hemoglobin, Glycosylated hemoglobin in percent will be measure with enzymatic assay using hexokinase reaction., Change from baseline Glycosylated hemoglobin at 12 weeks.]|Homeostasis Model Assessment of insulin resistance, Homeostasis Model Assessment of insulin resistance in units will be calculated with Fasting blood sugar and insulin., Change from baseline Homeostasis Model Assessment of insulin resistance at 12 weeks.]|Creatinine, Creatinine in mg/dl will be measure with enzymatic assay, Change from baseline creatinine at 12 weeks.]|estimate Glomerular filtration rate, estimate Glomerular filtration rate in ml/min/1.73 m2 will be calculated by CKD-EPI formular according to National kidney foundation recommendation., Change from baseline estimate Glomerular filtration rate at 12 weeks.]|Cystatin C, Cystatin C in mg/L will be measure with particle enhanced Immunoturbidimetric assay, Change from baseline blood urea nitrogen at 12 weeks|Urine albumin creatinine ratio, Urine albumin creatinine ratio will be measure with Immunoturbidimetric assay, Change from baseline urine albumin creatinine ratio at 12 weeks.|Stroop test, Stroop test in second will be measured with EncephalApp - Stroop Test, Change from baseline Stroop test in second at 12 weeks.
Secondary Outcome Measures: Waist circumference, Waist circumference in inch will be measure by waist tape, Change from baseline waist circumference at 12 weeks]|.Flexibility testing, Flexibility testing will be measure by Chair sit \& reach protocol in centimeters., Change from baseline Chair sit & reach at 12 weeks.]|Muscle strength testing, Muscle strength testing will be measured by arm-curl test repetitions in 30 seconds, Change from baseline arm-curl and chair stand at 12 weeks.]|Muscle strength testing, Muscle strength testing will be measured by arm-curl test and chair stand test in repetitions in 30 seconds, Change from baseline arm-curl and chair stand at 12 weeks.]|Balance testing, Balance testing will be measured by time up and go testing in seconds., Change from baseline time up and go at 12 weeks.]|Cardiopulmonary fitness, Cardiopulmonary fitness will be measure by 6-minutes walk test in meters., Change from baseline 6-minutes walk at 12 weeks.]|Lipid profile, Lipid profile will be measure by cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein in mg/dl., Change from baseline Nitric oxide at 12 weeks.] cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein at 12 weeks.]|Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase., Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase in pg/ml will be measure with ELISA assay kit., Change from baselineInterleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase. at 12 weeks.]|Nitric oxide, Nitric oxide in µM will measured with standard Griess reagents., Change from baseline Nitric oxide at 12 weeks.|Quality of life in patients with chronic kidney disease, Quality of life will be measured by SF-36 questionnaire for evaluation of Quality of Life in patients with chronic kidney disease. The scores of questionnaires were 75-100 points for good quality of life, 50-75 points for moderate quality of life, 25-50 points for low quality of life and 0-25 points for very low quality of life., Change from baseline at 12 weeks.|Flexibility testing, Flexibility testing will be measure by back scratch in centimeters., Change from baseline back scratch at 12 weeks.|Muscle strength testing, Muscle strength testing will be measured by chair stand test in repetitions in 30 seconds, Change from baseline chair stand at 12 weeks.]|Body mass index (BMI), Body mass index (BMI) through height and weight measurement by body composition analyzer weight and height will be combined to report BMI in kg/m\^2., Change from baseline BMI at 12 weeks.